jueves, 20 de julio de 2017

Serologic Evidence of Powassan Virus Infection in Patients with Suspected Lyme Disease1 - Volume 23, Number 8—August 2017 - Emerging Infectious Disease journal - CDC

Serologic Evidence of Powassan Virus Infection in Patients with Suspected Lyme Disease1 - Volume 23, Number 8—August 2017 - Emerging Infectious Disease journal - CDC

Volume 23, Number 8—August 2017


Serologic Evidence of Powassan Virus Infection in Patients with Suspected Lyme Disease1

Holly M. FrostComments to Author , Anna M. Schotthoefer, Angela M. Thomm, Alan P. Dupuis, Sue C. Kehl, Laura D. Kramer, Thomas R. Fritsche, Yvette A. Harrington, and Konstance K. Knox
Author affiliations: Marshfield Clinic Research Foundation, Minocqua, Wisconsin, USA (H.M. Frost)Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA (H.M. Frost, A.M. Schotthoefer, T.R. Fritsche)Coppe Laboratories, Waukesha, Wisconsin, USA (A.M. Thomm, Y.A. Harrington, K.K. Knox)New York State Department of Health, Slingerlands, New York, USA (A.P. Dupuis II, L.D. Kramer)Medical College of Wisconsin, Milwaukee, Wisconsin, USA (S.C. Kehl)


Powassan virus (POWV) lineage II is an emerging tickborne flavivirus with an unknown seroprevalence in humans. In a Lyme disease–endemic area, we examined the seroreactivity to POWV in 2 patient cohorts and described the clinical features of the POWV-seroreactive patients. POWV disease might be less neuroinvasive than previously thought.
Powassan virus (POWV) lineage II, also known as deer tick virus, is an emerging tickborne flavivirus (1) transmitted by Ixodes scapularis ticks, which are also the primary vector for Borrelia burgdorferi (Lyme disease pathogen). In POWV-endemic regions, up to 7% of ticks carry the virus, and seroprevalence among small mammalian hosts can exceed 90% (2,3). Because the territory of I. scapularis is expanding and the prevalence of POWV in ticks and mammals is increasing, POWV poses an increasing threat (25). The seroprevalence of POWV in humans in some regions of North America is known (range 0.5%–3.3%), but because the geographic distribution is quite extensive, the seroprevalence of most at-risk populations is uncertain (6).
POWV is typically detected with an IgM antibody capture ELISA or an IgM immunofluorescence antibody (IFA) assay. Cases are confirmed by >90% or >50% plaque reduction neutralization test (PRNT90 or PRNT50), detection of virus-specific nucleic acids, isolation in culture, or a >4-fold increase in antibody titers from paired acute and convalescent sera (79). Using these assays, investigators have identified ≈100 cases of POWV encephalitis; however, the actual incidence is likely higher (1,6). Although nonneuroinvasive disease has been described for other arboviral illnesses, our knowledge of POWV has been limited to patients with neuroinvasive disease (1,8,10,11). In this study, we evaluated the seroreactivity for POWV in US Midwest patients, many of whom did not have neuroinvasive disease.

The Study

We selected patients with suspected tickborne disease (TBD; n = 95) and patients undergoing routine chemical screening (n = 50) who sought treatment during July–August 2015 at the Marshfield Clinic in northern Wisconsin, a TBD-endemic area. Patients were considered to have suspected TBD if a serologic test for B. burgdorferi was ordered. The chemical screening cohort included patients who had a complete metabolic or lipid panel ordered as part of their clinical care. We evaluated POWV seroreactivity of specimens from these patient cohorts and, of the patients with serologic evidence of POWV infection and available clinical data, described the clinical features of their disease. All human subject research protocols were approved by the Marshfield Clinic Research Institute Institutional Review Board.
Thumbnail of Flow chart showing series of tests performed on specimens obtained from patients with suspected TBD and patients undergoing routine chemical screening to determine POWV seroreactivity, Wisconsin, July–August 2015. *Performed for TBD samples positive for POWV IgG or IgM and chemical screening samples positive for POWV IgM by IFA assay. †Performed for samples positive for POWV IgG by IFA assay. IFA, immunofluorescence antibody assay; POWV, Powassan virus; PRNT90, >90% plaque reduct
Figure. Flow chart showing series of tests performed on specimens obtained from patients with suspected TBD and patients undergoing routine chemical screening to determine POWV seroreactivity, Wisconsin, July–August 2015. *Performed for TBD...
We performed screening assays on all specimens for tick-borne encephalitis virus complex (TBEV-C) and B. burgdorferi and performed POWV serology on TBEV-C–positive specimens (Figure; detailed methods in Technical Appendix[PDF - 174 KB - 2 pages]). To evaluate heterologous flavivirus cross-reactivity, we performed the West Nile virus (WNV) enzyme immunoassay (EUROIMMU, Mountain Lakes, NJ, USA) with TBEV-C–positive samples. We also performed the Flavivirus Mosaic Panel (EUROIMMUN), an IgG IFA assay panel including tests for TBEV, WNV, yellow fever virus, dengue viruses 1–4, and Japanese encephalitis virus, on samples positive for POWV IgG by the IFA assay. Patient vaccination status and travel history were also considered.
Clinical data were available for 51 (53.7%) TBD patients and 50 (100%) patients tested by chemical screening with routine chemistry screening completed. For those with clinical data available, we classified their cases as probable or confirmed by using the Centers for Disease Control and Prevention case definitions (7). We performed statistical analysis with SAS 9.3 (SAS Institute, Inc., Cary NC, USA) and compared categorical variables by using Fisher exact tests. Significance was defined as p<0.05.
Serologic evidence of POWV infection was present in 9 (9.5%) TBD patients and 2 (4.0%) patients with routine chemistry screening completed (p = 0.33) (Table 1). POWV infection was confirmed in 3 (3.2%) TBD patients (2 by PRNT90 [titer range 1:160–1:320] and 1 by reverse transcription PCR) and 0 chemical screening patients (p = 0.55). Of the 3 patients with confirmed POWV infection, evidence of acute infection (IgM positivity) was found in 2 (2.7%). Patients positive only for IgM by IFA assay did not have PRNT90 titers, which was expected because neutralizing antibodies are often not present during early infection (12). The 2 patients with routine chemistry screening completed who were positive for POWV IgG failed to show neutralization by PRNT; however, rather than PRNT50, we used POWV PRNT90, which has greater specificity but lower sensitivity. In addition, our PRNT was based on POWV lineage I; thus, our test was potentially less sensitive at detecting POWV lineage II–specific antibodies and thus less capable of detecting previous POWV lineage II infection.
Similar to other flavivirus serologic assays, considerable cross-reactivity occurred with the Flavivirus Mosaic IgG IFA assay (Technical Appendix[PDF - 174 KB - 2 pages] Table) (13). The fluorescence intensity was stronger for TBEV than it was for other flaviviruses in all TBD patients except for 1 patient with prior confirmed WNV infection. Both patients with routine chemistry screening completed who were POWV IgG–positive were TBEV IgM–positive. Neither had a history of yellow fever or dengue virus exposure or vaccination, although the panel showed cross-reactivity with these viruses.
Evidence of current or prior B. burgdorferi infection was present in 63 (66.3%) TBD patients and 4 (8%) patients with routine chemistry screening completed (p<0.0001). Of the 41 (43.2%) TBD patients with evidence of B. burgdorferi infection, 7 (17.1%) had serologic evidence of acute POWV infection and 3 (7.3%) had laboratory-confirmed POWV infection. When controlling for differences in seroprevalence rates of B. burgdorferi, no statistical differences were evident for POWV seroprevalence (p = 1.0) or confirmed infections (p = 1.0) between patients with routine chemistry screening completed and TBD patients, although the study was underpowered in this regard.
B. burgdorferi IgM was detected in 6 (85.7%) of the 7 patients with serologic evidence of acute POWV infection, suggesting concurrent infection, which is consistent with surveillance data indicating that POWV and B. burgdorferi co-infect I. scapularis ticks (2,3). The rate of concurrent antibodies we report is higher than that described for regions of Europe endemic for TBE and Lyme disease (14).
Clinical data were available for 7 of the patients with serologic evidence of POWV infection (Table 2). Infection probably occurred in 3 patients. A laboratory-confirmed nonacute infection was found in a patient (patient no. 2) who did not meet Centers for Disease Control and Prevention criteria. Patient symptoms could not be attributed specifically to POWV because all TBD patients with clinical data available were positive for B. burgdorferiantibodies, and testing for the possibility of infection with additional endemic tick pathogens was performed for only 2 patients.
Consistent with previous studies showing increased susceptibility of children to arboviral diseases, 3 patients who might have had POWV infection were children (Table 2) (15). Fever was present in all patients with evidence of POWV acute infection; other common symptoms were fatigue, malaise, fussiness, listlessness, and headache. Complete blood cell count and C-reactive protein did not indicate severe infection. Consistent with other arboviral diseases, urticarial or maculopapular rash was documented in 3 patients (15). No patients had neuroinvasive disease.
This study had limitations. Similar to other serologic studies, cross-reactivity and prior exposure to POWV cannot be completely excluded in serologically positive cases. Analysis for other flaviviruses, prior yellow fever virus vaccination, and history of travel to dengue-endemic regions, as well as PRNT, were completed to address this concern. The study population was limited to persons in the US upper Midwest, although POWV is likely an increasing problem throughout the territory I. scapularis ticks occupy. Our study results might not be applicable to these other regions.


In a Lyme disease–endemic area, POWV seroreactivity and confirmed POWV infection were present. The spectrum of disease is broader than previously realized, with most patients having minimally symptomatic infection (1,10,11). Further studies are needed to characterize clinical disease of POWV monoinfection, document POWV seroprevalence in humans, and monitor epidemiologic trends.
Dr. Frost is a pediatrician and physician scientist at Marshfield Clinic in Minocqua, Wisconsin. Her research interests include tickborne pathogens, blastomycosis, and antimicrobial stewardship.


We thank Marshfield Clinic Research Foundation staff for supporting this study and Marshfield Labs staff for collecting specimens. We also thank Diep Johnson for assisting with this study.


  1. Piantadosi ARubin DBMcQuillen DPHsu LLederer PAAshbaugh CDet al. Emerging cases of Powassan virus encephalitis in New England: clinical presentation, imaging, and review of the literature. Clin Infect Dis2016;62:70713DOIPubMed
  2. Dupuis AP IIPeters RJPrusinski MAFalco RCOstfeld RSKramer LDIsolation of deer tick virus (Powassan virus, lineage II) from Ixodes scapularisand detection of antibody in vertebrate hosts sampled in the Hudson Valley, New York State. Parasit Vectors2013;6:185DOIPubMed
  3. Knox KThomm AHarrington YBaewer DCarrigan D. Arbovirus co-infections in Wisconsin tick populations. Poster presentation at: IDWeek; October 7–11, 2015; San Diego, CA, USA.
  4. Eisen RJEisen LBeard CBCounty-scale distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the continental United States. J Med Entomol2016;53:34986DOIPubMed
  5. Nofchissey RADeardorff ERBlevins TMAnishchenko MBosco-Lauth ABerl Eet al. Seroprevalence of Powassan virus in New England deer, 1979-2010. Am J Trop Med Hyg2013;88:115962DOIPubMed
  6. Ebel GDUpdate on Powassan virus: emergence of a North American tick-borne flavivirus. Annu Rev Entomol2010;55:95110DOIPubMed
  7. Centers for Disease Control and Prevention. Arboviral diseases, neuroinvasive and non-neuroinvasive 2015 case definition [cited 2017 Feb 12]. https://wwwn.cdc.gov/nndss/conditions/arboviral-diseases-neuroinvasive-and-non-neuroinvasive/case-definition/2015/
  8. El Khoury MYHull RCBryant PWEscuyer KLSt George KWong SJet al. Diagnosis of acute deer tick virus encephalitis. Clin Infect Dis2013;56:e407DOIPubMed
  9. Thomm ASchotthoefer AKehr SKramer LFrost HFritsche Tet al. Development of a serologic test panel for detection of Powassan virus infection. Poster presented at: The 32st Clinical Virology Symposium; May 19–22, 2016; Dayton Beach, FL, USA [cited 2017 Feb 12]. http://www.abstractsonline.com/pp8/#!/4039/presentation/725
  10. Neitzel DFLynfield RSmith KPowassan virus encephalitis, Minnesota, USA. Emerg Infect Dis2013;19:686DOIPubMed
  11. Sung SWurcel AGWhittier SKulas KKramer LDFlam Ret al. Powassan meningoencephalitis, New York, New York, USA. Emerg Infect Dis2013;19DOIPubMed
  12. Venturi GMartelli PMazzolini EFiorentini CBenedetti ETodone Det al. Humoral immunity in natural infection by tick-borne encephalitis virus. J Med Virol2009;81:66571DOIPubMed
  13. Ledermann JPLorono-Pino MAEllis CSaxton-Shaw KDBlitvich BJBeaty BJet al. Evaluation of widely used diagnostic tests to detect West Nile virus infections in horses previously infected with St. Louis encephalitis virus or dengue virus type 2. Clin Vaccine Immunol2011;18:5807DOIPubMed
  14. Gustafson REpidemiological studies of Lyme borreliosis and tick-borne encephalitis. Scand J Infect Dis Suppl1994;92:163.PubMed
  15. Davis LEBeckham JDTyler KLNorth American encephalitic arboviruses. Neurol Clin2008;26:72757, ixDOIPubMed



Technical Appendix

Cite This Article

DOI: 10.3201/eid2308.161971
1Preliminary results from this study were presented at IDWeek; October 26–30, 2016; New Orleans, Louisiana, USA.

No hay comentarios:

Publicar un comentario